A phase1/2a trial to investigate the neoantigen cancer vaccine GEN-009
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs GEN 009 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 15 Feb 2018 According to a Genocea Biosciences media release, the company expects to intiate this study in mid of 2018. In the first part of this trial, company expects to enroll 6 patients.
- 25 Sep 2017 According to a Genocea Biosciences media release, the company expects to file an Investigational New Drug (IND) application for GEN-009 by early 2018 and plans to initiate a phase I trial in a range of tumor types in the first half of 2018 and expects to report initial immunogenicity data in the first half of 2019.
- 20 Feb 2017 New trial record